HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

5th Edition of Cardiology World Conference

September 5-7, 2024 | Madrid, Spain

September 05 -07, 2024 | Madrid, Spain
Cardio 2024

Naranjan Dhalla

Naranjan Dhalla, Speaker at Cardiology Conferences
St. Boniface Hospital Albrechtsen Research Centre, Canada
Title : Antiplatelet agents as a novel therapy of heart failure due to myocardial infarction


Although different antiplatelet agents are used for the prevention of thrombosis and treatment of ischemic heart disease, very little information regarding therapeutic potential of these agents in heart failure is available. We have investigated the effects of some antiplatelet agents such as sarpogrelate (SAR) and cilostazol (CIL) treatments on cardiac dysfunction, cardiac remodeling and subcellular defects in heart failure due to myocardial infection. Heart failure in rats was induced by including the coronary artery for 8 weeks and the drug treatment was started 4 weeks after inducing myocardial infarction. Marked depression in cardiac output and ejection fraction as well as increases in heart rate, left ventricle (LV) thickness and LV volume in the infarcted animals were attenuated by SAR and CIL. Alterations in myofibril Ca2+-ATPase, as well as myosin isozyme contents and gene expression in the failing heart were reduced by SAR and CIL. Likewise, changes in sarcoplasmic reticular Ca2+-uptake and release activities, Ca2+-pump and Ca2+-release protein content as well as their mRNA levels were attenuated by both drug treatments. These results provide evidence that both SAR and CIL delay the progression of heart failure and improve cardiac function by attenuating cardiac remodeling, subcellular defects and abnormalities in cardiac gene expression. It is suggested that antiplatelet agents may prove to be a viable therapy for the treatment of heart failure.


Dr. Naranjan Dhalla is a leading expert in the field of heart research, with a focus on understanding the causes of cardiac dysfunction. He has made significant contributions to our understanding of the cellular and molecular mechanisms underlying heart disease, including the role of oxidative stress, changes in gene expression, and intracellular calcium overload. One of the key findings of Dr. Dhalla's research is the connection between oxidative stress and the development of ischemia-reperfusion injury, a major cause of heart disease. He has also shown that catecholamines, which are hormones produced in response to stress, can cause cardiac dysfunction and lethal arrhythmias. Using cutting-edge research techniques, Dr. Dhalla has shed light on the complex interactions between the heart, its cells, and the signaling pathways that govern its function. His work has identified new targets for drug development, offering hope for the development of more effective therapies for heart disease.